Coconut oil's effect on hair loss in breast cancer patients
The Effect of Coconut Oil on Alopecia in Women Receiving Doxorubucin-Cycylophosphamide Treatment for Breast Cancer
This study is testing if coconut oil can help reduce hair loss in women with breast cancer who are receiving chemotherapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 86 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | Female |
| Sponsor | Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital Academic / other |
| Drugs / interventions | chemotherapy, Cyclophosphamide, Doxorubicin |
| Locations | 1 site (Ankara, Yenimahalle) |
| Trial ID | NCT06818370 on ClinicalTrials.gov |
What this trial studies
This study evaluates the impact of coconut oil on alopecia in 86 female breast cancer patients undergoing chemotherapy with the Doxorubicin-Cyclophosphamide protocol. Conducted at Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, the study aims to assess whether coconut oil can mitigate hair loss associated with cancer treatments. Participants will be monitored for changes in hair regrowth and overall scalp health, utilizing established scales for alopecia evaluation. The study is set to take place from February 1, 2025, to December 31, 2025.
Who should consider this trial
Good fit: Ideal candidates are women aged 18 and older diagnosed with breast cancer who are scheduled to receive the Doxorubicin-Cyclophosphamide chemotherapy regimen.
Not a fit: Patients who have previously experienced hair loss due to other conditions or have received prior chemotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a natural and effective method to reduce chemotherapy-induced hair loss in breast cancer patients.
How similar studies have performed: While there is limited literature on the effects of coconut oil for alopecia, this approach is relatively novel and has not been extensively tested in this specific context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * • To have been diagnosed with breast cancer. * The chemotherapy treatment plan should be planned as the Doxorubicin-Cyclophosphamide protocol. * Volunteer to participate in the study. * Be 18 years of age or older. * Being a woman. Exclusion Criteria: * • Having any health problem or disability that prevents communication (vision-hearing problems, neurological, psychiatric diseases). * Planning other treatments other than the Doxorubicin-Cyclophosphamide protocol for the treatment of breast cancer. * Not volunteering to participate in the study. * Having previously experienced any disease/skin problem that causes hair loss. * Having received chemotherapy before.
Where this trial is running
Ankara, Yenimahalle
- Dr. Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi — Ankara, Yenimahalle, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: İsmail Dakdevir, Nurse
- Email: dakdevirismail@gmail.com
- Phone: +905533228416
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.